Tillman Gerngross (Craig F. Walker/The Boston Globe via Getty Images)
October 17, 2022 07:12 AM EDT
People

For­mer Till­man Gern­gross Covid-19 an­ti­body start­up cuts costs and head­count again, one month af­ter re­brand

Max Gelman

Senior Editor

The com­pa­ny for­mer­ly known as Ada­gio has run in­to an­oth­er speed bump.

In­vivyd, which re­brand­ed last month in an at­tempt to shed its trou­bled rep­u­ta­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times